{
    "pmcid": "11609190",
    "qa_pairs": {
        "How does the infectivity of the SARS-CoV-2 variant KP.3 compare to JN.1?": [
            "KP.3 is less infectious than JN.1",
            "KP.3 is more infectious than JN.1",
            "KP.3 and JN.1 have the same level of infectivity",
            "KP.3 is not infectious"
        ],
        "What delivery method is suggested for nanobodies to enhance therapeutic concentrations at the site of infection?": [
            "Inhalation delivery",
            "Intravenous injection",
            "Oral administration",
            "Topical application"
        ],
        "What is a proposed advantage of using nanobodies for targeting SARS-CoV-2 variants like JN.1 and KP.3?": [
            "Nanobodies can access hidden epitopes with their extended CDR3 regions",
            "Nanobodies are larger and more stable than conventional antibodies",
            "Nanobodies are less specific and can bind to any viral protein",
            "Nanobodies are more expensive to produce than conventional antibodies"
        ],
        "What is the notable mutation in the spike protein of the SARS-CoV-2 variant JN.1?": [
            "Leu455Ser",
            "Gly614Asp",
            "Asp614Gly",
            "Pro681His"
        ],
        "Where was the SARS-CoV-2 variant JN.1 first detected?": [
            "Luxembourg",
            "United States",
            "South Africa",
            "Brazil"
        ]
    }
}